Leprosy Mailing List – September 23, 2020
Ref.: (LML) Post-exposure prophylaxis (PEP) efficacy of rifampin, rifapentine, moxifloxacin, minocycline, and clarithromycin in a susceptible-subclinical model of leprosy
From: Pieter AM Schreuder, Maastricht, the Netherlands
Dear colleagues,
Dr. Naafs sent me the following article – of much interest regarding the point Joel Almeida is making in his recent letters.
Post-exposure prophylaxis (PEP) efficacy of rifampin, rifapentine, moxifloxacin, minocycline, and clarithromycin in a susceptible-subclinical model of leprosy. By Shannon M. Lenz, Jaymes H. Collins, Nashone A. Ray, Deanna A. Hagge, Ramanuj Lahiri and Linda B. Adams
https://doi.org/10.1371/journal.pntd.0008583
https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0008583
Conclusions/Significance
The delay in discernible M. leprae growth post-treatment was an excellent indicator of drug efficacy for both early (3–4 months) and late (8–9 months) drug efficacy. Our data indicates that multi-dose PEP may be required to control infection in highly susceptible individuals with subclinical leprosy to prevent disease and decrease transmission.
Regards,
Pieter AM Schreuder
LML - S Deepak, B Naafs, S Noto and P Schreuder
LML blog link: http://leprosymailinglist.blogspot.it/
Contact: Dr Pieter Schreuder << editorlml@gmail.com
--You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web, visit https://groups.google.com/d/msgid/leprosymailinglist/310d55e8-4a6a-46d0-82c7-be96be782fb1n%40googlegroups.com.
No comments:
Post a Comment